FDA Issues Draft Guidance to Accelerate Cell and Gene Therapy Development Using Prior Knowledge

On 2 June 2026 the U.S. Food and Drug Administration (FDA) released a draft guidance aimed at speeding the development of cell and gene therapy (CGT) products that employ genome editing in human somatic cells. The document outlines how sponsors may incorporate publicly available information, established platform data, chemistry-manufacturing-controls (CMC) records, non-clinical study results, and clinical experience to streamline regulatory submissions. The agency invites public comment for 90 days after publication in the Federal Register.

FDA - Food and Drug AdministrationPharmaphorumFDA aims to speed gene therapy development with prior scientific knowledge guidance

The guidance is part of the FDA’s broader effort under the Prescription Drug User Fee Amendments VII (PDUFA VII) to reduce barriers for CGTs targeting rare, life-threatening diseases. Earlier in 2026 the agency issued draft guidance on off-target editing risks for genome-editing therapies and introduced a “plausible mechanism” framework for ultra-rare indications, as well as measures to simplify CGT manufacturing. Together, these actions seek to align regulatory pathways with rapidly evolving scientific capabilities.

Pharmaphorum

• Karim Mikhail, Acting Director, Center for Biologics Evaluation and Research (CBER) – primary spokesperson for the draft guidance.

FDA - Food and Drug Administration

• Vijay Kumar, Acting Director, CBER Office of Therapeutic Products – provided additional commentary on the safety-efficacy balance.

FDA - Food and Drug Administration

• CBER – the FDA center responsible for biologics, including CGTs, that authored the guidance.

FDA - Food and Drug Administration

The draft defines three categories of prior knowledge: public knowledge, platform knowledge, and prior knowledge specific to a product. While the guidance focuses on ex vivo and in vivo genome-editing products, it states that the principles may extend to adeno-associated viral (AAV) vectors, nanoparticle-based gene therapies, and ex vivo-modified cell products that do not involve editing. Sponsors are encouraged to engage early—through mechanisms such as the Initial Targeted Engagement for Regulatory Advice on CBER/CDER Products (INTERACT) and pre-IND meetings—to discuss leveraging strategies and submit justification proposals for FDA review.

FDA aims to speed gene therapy development with prior scientific knowledge guidance

The FDA emphasizes that leveraging prior knowledge is intended to improve review efficiency without compromising safety or efficacy standards. Agency officials stress that the approach “raises collective efficiency while maintaining the highest standards of safety and efficacy” and that timely access to therapies is critical for patients with serious or rare diseases. The guidance invites developers to submit leveraging proposals for consideration and to participate in the public comment process.

Pharmaphorum

Sources do not provide quantitative estimates of how much development time or cost the guidance might save, nor do they include stakeholder feedback or independent assessments of the proposed framework. No explicit criticism or opposition is recorded in the available material, leaving an evidentiary gap regarding potential concerns about safety oversight or implementation challenges.

Pharmaphorum

• “Today’s action reflects the FDA's commitment to get safe and effective cell and gene therapies to patients faster, particularly those living with rare and life-threatening diseases who have few or no other treatment options,” — Karim Mikhail, Acting Director, CBER

FDA - Food and Drug Administration

• “Leveraging prior knowledge does not mean lowering the bar; it means raising our collective efficiency while maintaining the highest standards of safety and efficacy,” — Vijay Kumar, Acting Director, Office of Therapeutic Products

Pharmaphorum

• “For patients living with serious or rare diseases, time matters,” — Vijay Kumar, Acting Director, Office of Therapeutic Products

Pharmaphorum

• “This guidance is being released as part of a [Prescription Drug User Fee Amendments (PDUFA VII)] commitment to publish guidance on leveraging prior knowledge for cell and GT (CGT) products,” — FDA

FDA aims to speed gene therapy development with prior scientific knowledge guidance

• “Sponsors should submit any leveraging proposals to FDA for consideration, and, if desired, discussion (see section IV),” — FDA

FDA aims to speed gene therapy development with prior scientific knowledge guidance

Comments on the draft must be filed through Regulations.gov by early September 2026. Following review of stakeholder input, the FDA plans to finalize the guidance, which could become a reference point for future CGT submissions and potentially influence the design of early-stage development programs across the industry.

FDA - Food and Drug Administration